Key result
POLARx cryoballoon achieves ~97% acute pulmonary vein isolation in paroxysmal AF.
Why the study?
Real-world acute procedural efficacy and safety data were needed for a novel cryoballoon used for pulmonary vein isolation in paroxysmal atrial fibrillation.
Does the POLARx cryoballoon system achieve high acute procedural pulmonary vein isolation efficacy and acceptable 3-month safety in patients with symptomatic paroxysmal atrial fibrillation?
Cohort (n=372)
non-randomized
Yes
Does the POLARx cryoballoon system achieve high acute procedural pulmonary vein isolation efficacy and acceptable 3-month safety in patients with symptomatic paroxysmal atrial fibrillation?
In a large multicenter European registry of 372 de novo paroxysmal AF ablations, the novel POLARx cryoballoon demonstrated high acute PV isolation (96.8%), short procedure time (68.2 min), and a low 3-month complication rate (3.3%) despite achieving colder nadir temperatures (-56.6°C) than traditional cryoballoons.
Answers are grounded in this paper and cite their sources.
POLARx was associated with high acute PVI rates and low early complications in paroxysmal AF; leaves open randomized comparisons to established cryoballoons.
INTRODUCTION: cryoballoon for PVI to treat paroxysmal AF. METHODS: POLAR ICE, a prospective, non-randomized, multicenter (international) registry (NCT04250714), enrolled 399 patients across 19 European centers. Procedural characteristics, such as time to isolation, cryoablations per pulmonary vein (PV), balloon nadir temperature, and occlusion grade were recorded. PVI was confirmed with entrance block testing. RESULTS: Data on 372 de novo PVI procedures (n = 2190 ablations) were collected. Complete PVI was achieved in 96.8% of PVs. Procedure and fluoroscopy times were 68.2 ± 24.6 and 15.6 ± 9.6 min, respectively. Left atrial dwell time was 46.6 ± 18.3 min. Grade 3 or 4 occlusion was achieved in 98.2% of PVs reported and 71.2% of PVs isolation required only a single cryoablation. Of 2190 cryoapplications, 83% had a duration of at least 120 s; nadir temperature of these ablations averaged -56.3 ± 6.5°C. There were 6 phrenic nerve palsy events, 2 of which resolved within 3 months of the procedure. CONCLUSION: This real-world usage data on a novel cryoballoon suggests this device is effective, safe, and relatively fast in centers with cryoballoon experience. These data are comparable to prior POLARx reports and in keeping with reported data on other cryoballoons. Future studies should examine the long-term outcomes and the relationship between biophysical parameters and outcomes for this novel cryoballoon.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2023) conducted a cohort in Paroxysmal atrial fibrillation (n=372). POLARx cryoballoon ablation system for pulmonary vein isolation was evaluated on Acute procedural success (complete pulmonary vein isolation confirmed by entrance block testing). POLARx cryoballoon ablation achieved complete pulmonary vein isolation in 96.8% of targeted veins and a 3.3% 3-month safety event rate in paroxysmal atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: